Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy in ICU patients with renal insufficiency
NL-OMON20378Not yet recruiting
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in contrast-induced nephropathy (CIN) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoints: Contrast-induced nephropathy by creatinine rise, Need for CVVH therapy and 2 more. Planned start Jan 2006; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NL-OMON20378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20378.